3SBio Given SFDA Permission for Phase III Trial of Anti-Rejection Drug
3SBio received permission from the SFDA to conduct the China arm of the multi-national Phase III trial of voclosporin, a new generation calcineurin inhibitor. 3SBio in-licensed the drug from Isotechnika Pharma of Canada in 2010. The drug suppresses immune system activity and will be tested in patients undergoing renal transplants. More details... Stock Symbols: (NSDQ: SSRX) (TSX: ISA) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here